Drug class
Oral direct thrombin inhibitor prodrug; anticoagulant
Mechanism of action
Dabigatran etexilate is an orally administered prodrug converted by esterases to dabigatran, a direct, competitive inhibitor of free and clot-bound thrombin. Thrombin inhibition prevents fibrin formation and thrombin-mediated platelet activation.
General use cases
- Prevention of stroke and systemic embolism in eligible adults with non-valvular atrial fibrillation
- Treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) after initial parenteral anticoagulation, and reduction of recurrent DVT/PE risk
- Primary prevention of venous thromboembolic events after hip replacement surgery in adults; paediatric indications and dosing are product-label specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
